Thyrocare Technologies board approved the sale of its entire stake in Nucleur Healthcare Limited to Trovera Healthcare for ₹141.4 crore, allowing the company to sharpen its focus on its core pathology business.

Transaction details

The board sanctioned the divestment of Thyrocare Technologies' full shareholding in Nucleur Healthcare Limited, a material wholly owned subsidiary, to Trovera Healthcare Private Limited. The deal is valued at ₹141.4 crore. The transaction marks a strategic exit from the radiology and diagnostic imaging segment, redirecting the company's focus toward its primary pathology operations.

The consideration comprises:

• ₹59.5 crore in 42,500 Compulsorily Convertible Preference Shares (CCPS) of Trovera, issued at ₹14,000 per share.
• Approximately ₹81.9 crore in cash, subject to working capital adjustments as per the Share Purchase Agreement (SPA).

The valuation was undertaken by V. B. Desai Financial Services Limited, a SEBI-registered Category-I Merchant Banker. The transaction is not a related party transaction but requires shareholder approval via a Special Resolution under Regulation 37A of the SEBI Listing Regulations.

Subsidiary financials

Nucleur Healthcare Limited (NHL) contributed significantly to Thyrocare's consolidated metrics in FY26. The following table summarises NHL's financial performance for the fiscal year ended March 31, 2026:

For context, Thyrocare's standalone PAT margin stood at 19.2% in FY26. The divestment removes a unit with lower profitability margins from the consolidated group.

Property acquisitions approved

Alongside the divestment, the board also approved the purchase of properties in two cities from NHL itself, prior to or simultaneously with the sale. This ensures Thyrocare retains ownership of its operating premises. The following table summarises the approved property transactions:

The aggregate consideration for these immovable properties is ₹20.59 crore, exclusive of stamp duty and registration charges. The valuation was determined by Mr. Anil Kumar, a Registered Valuer. Since NHL is a wholly owned subsidiary, this purchase constitutes a related party transaction conducted at arm's length.

Strategic focus on core pathology business

The sale of the stake in Nucleur Healthcare Limited reflects the company's intent to concentrate resources on its core pathology segment. By divesting the nuclear healthcare unit, Thyrocare Technologies aims to streamline its business portfolio. The concurrent property purchases in Gurugram and Hyderabad indicate continued investment in the company's primary business operations.

What the Numbers Show

The divestment highlights a divergence in profitability between the parent and the subsidiary. While NHL generated ₹44.62 crore in turnover (5.38% of consolidated), its PAT margin of 10.9% is less than half of Thyrocare’s standalone margin of 19.2%. Exiting this lower-margin segment should accretively impact consolidated profitability ratios, assuming the cash and CCPS consideration is deployed efficiently or held as liquid assets.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE594H01019/80d27be9-f0c0-4da2-852c-2e2ea5e227e2.pdf

API Holdings Limited has submitted an updated disclosure to stock exchanges regarding the release of pledge on 7,94,69,696 equity shares of Thyrocare Technologies .

The filing, dated September 8, 2026, serves as an update to a previous disclosure made by Docon Technologies Private Limited on August 17, 2026. Docon had pledged its entire shareholding in Thyrocare to secure obligations related to Non-Convertible Debentures (NCDs) issued by API Holdings.

Pledge Release Details

As on August 17, 2026, the entire pledge created by Docon over its 7,94,69,696 equity shares in Thyrocare was fully released. The shares were pledged in favor of Catalyst Trusteeship Limited, acting as the Debenture Trustee. There were no outstanding pledges or other encumbrances over the shares held by Docon at that time.

Amalgamation Context

The updated disclosure was filed by API Holdings following the implementation of a court-approved amalgamation scheme. The National Company Law Tribunal (NCLT), Mumbai Bench, sanctioned the merger of Docon with API on August 31, 2026. The scheme became effective on September 3, 2026, after the certified order was filed with the Registrar of Companies.

Under the scheme, all assets, liabilities, and undertakings of Docon were transferred to API. Consequently, Docon ceased to exist, and API became the successor entity. API now holds the controlling stake previously held by Docon.

Regulatory Compliance

The disclosure was made pursuant to Regulations 31(2) and 31(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. API Holdings stated that the filing is required because it is the successor to Docon, which had originally created and released the pledge.